Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study

NCT05277766 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT05277766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05277766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study
Lead sponsor
University Hospital, Ghent
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 21, 2022
Completion date
August 1, 2027
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

appendix cancer, bile duct cancer, colorectal cancer, gastric cancer, pancreatic cancer, peritoneal carcinomatosis, peritoneal metastases, small bowel cancer